Sandbox/002: Difference between revisions
< Sandbox
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) m (/* Pathogen-Based Therapy Adapted from Circulation 2008;118(15):e523-661.{{Cite journal | last1 = Bonow | first1 = RO. | last2 = Carabello | first2 = BA. | last3 = Chatterjee | first3 = K. | last4 = de Leon | first4 = AC. | last5 = Faxon | first5 = DP...) |
||
Line 120: | Line 120: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg IV q24h x 2 weeks''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg IV q24h (or 1 mg/kg IV q8h) x 2 weeks''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg/day IV q8—12h x 4 weeks'''''<sup>ǁ</sup> | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <sup>†</sup> Patients with endocarditis caused by penicillin-resistant (MIC greater than 0.5 μg/ml) strains should be treated with regimen recommended for enterococcal endocarditis. <BR> <sup>‡</sup> Recommended for enterococcal endocarditis. <BR> <sup>ǁ</sup> Vancomycin doses should not exceed 2 g per 24 h, unless serum concentrations are inappropriately low; recommended only for patients unable to tolerate penicillin or ceftriaxone therapy. | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <sup>†</sup> Patients with endocarditis caused by penicillin-resistant (MIC greater than 0.5 μg/ml) strains should be treated with regimen recommended for enterococcal endocarditis. <BR> <sup>‡</sup> Recommended for enterococcal endocarditis. <BR> <sup>ǁ</sup> Vancomycin doses should not exceed 2 g per 24 h, unless serum concentrations are inappropriately low; recommended only for patients unable to tolerate penicillin or ceftriaxone therapy. | ||
Line 132: | Line 132: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Viridans Streptococci'' or ''S. bovis'' NVE, PCN- | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Viridans Streptococci'' or ''S. bovis'' NVE, PCN-Resistant, Adult}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G sodium]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G sodium]] 0.3 MU/kg/day IV q4—6h x 4 weeks'''''<sup>†</sup> <BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg IV/IM q24h x 4 weeks'''''<sup>‡</sup> | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg IV q24h x 2 weeks''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg IV q24h (ddd x 2 weeks''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 4 weeks''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 4 weeks'''''<sup>ǁ</sup> | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <sup>†</sup> Patients with endocarditis caused by penicillin-resistant (MIC greater than 0.5 μg/ml) strains should be treated with regimen recommended for enterococcal endocarditis. <BR> <sup>‡</sup> Recommended for enterococcal endocarditis. <BR> <sup>ǁ</sup> Vancomycin doses should not exceed 2 g per 24 h, unless serum concentrations are inappropriately low; recommended only for patients unable to tolerate penicillin or ceftriaxone therapy. | |||
|} | |} | ||
|} | |} |
Revision as of 18:43, 5 March 2014
Endocarditis Microchapters |
Diagnosis |
---|
Treatment |
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
Case Studies |
Sandbox/002 On the Web |
Pathogen-Based Therapy Adapted from Circulation 2008;118(15):e523-661.[1]
Viridans Streptococci or Streptococcus bovis
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis ▸ Penicillin-Susceptible, Adult ▸ Penicillin-Susceptible, Pediatric ▸ Penicillin-Resistant, Adult ▸ Penicillin-Resistant, Pediatric Prosthetic Valve Endocarditis ▸ Penicillin-Susceptible, Adult ▸ Penicillin-Susceptible, Pediatric ▸ Penicillin-Resistant, Adult ▸ Penicillin-Resistant, Pediatric |
|
References
- ↑ Bonow, RO.; Carabello, BA.; Chatterjee, K.; de Leon, AC.; Faxon, DP.; Freed, MD.; Gaasch, WH.; Lytle, BW.; Nishimura, RA. (2008). "2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (13): e1–142. doi:10.1016/j.jacc.2008.05.007. PMID 18848134. Unknown parameter
|month=
ignored (help)